Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 12,001–12,100 of 12,156

1. Association of Multidisciplinary Care Team Engagement With Hemoglobin A1c Among Medicaid Enrollees With Diabetes: A Doubly Robust Machine Learning Analysis
   Sanjay Basu, Aaron Baum, Matthew Goldhirsh, John Morgan, Rajaie Batniji · 2026 · Diabetes Obesity and Cardiometabolic CARE
2. Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study
   Marwan A. Alrasheed, Bader M. Alhadhrami, Abdulaziz Abdullah Alqarni, Nawaf Mohammed Alghamdi, Omar A. Alfurayh, Omar A. Almohammed · 2026 · Frontiers in Endocrinology
3. Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction
   Sergio Raposeiras‐Roubín, Rafael Gonzalez-Manzanares, Ignacio Jesus Amat-Santos, María Melendo‐Viu, David Dobarro, Diego López‐Otero, Luis Nombela Franco, Livia Gheorge, Jorge Sanz-Sánchez y, Baladrón Zorita Carlos et al. · 2026 · European Journal of Heart Failure
4. Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting
   Cheng Cheng, Minghui Tang, 张兆波, Ruoyi Qu, Jianfei Pei, Tian Liu, Siyao Qu, Shilong You, Shenshen Cui, Wenke Wang et al. · 2026 · Advanced Science
5. Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study
   Ying Ran, Li-Li Jiang, Jing Ran, Yu Zhu, Lu-Pin Pan, Ba-Yi Yang, Xue Ran, He-Jun Ding, Shao-Fa Wu, Xia Ling · 2026 · Frontiers in Endocrinology
6. Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease
   Mie Jung Yoo, Shina Lee · 2026 · Electrolytes & Blood Pressure
7. Sodium–glucose cotransporter-2 inhibitor use and clinical outcomes in patients with cirrhosis: a propensity-matched real-world cohort study
   Engy Helal, Elona Shehi, Ahmad Al Homaid · 2026 · European Journal of Gastroenterology & Hepatology
8. Myocardial degeneration precedes fibrosis: The role of myocardial autophagy and its pathological evaluation
   Tsunenori Saito · 2026 · Journal of Cardiology
9. Antidiabetic medications and arterial thrombotic risk reduction: a narrative review
   Francesca Santilli, Paola Simeone, Rossella Liani · 2026 · Internal and Emergency Medicine
10. The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence
    Anna Celina Durma, Monika Blicharska, Leszek Czupryniak · 2026 · Diabetes Therapy
11. Trimetazidine in Chronic Coronary Syndrome and Coronary Artery Disease: A Narrative Review of Clinical Efficacy, Safety, and Current Guideline Position
    Daniel Miron Brie, Cristian Mornoş, Alexandru Tîrziu · 2026 · Pharmaceuticals
12. Seguridad y efectos reno-metabólicos del uso de inhibidores del transportador sodio-glucosa tipo 2 en pacientes con trasplante renal
    Natalia Campos-Ramírez, Luis Alfonso Mariscal-Ramírez, Jesús Arellano-Martínez · 2026 · Revista Mexicana de Trasplantes
13. A LITERATURE REVIEW OF SGLT2 INHIBITORS IMPACT ON MAJOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER AND PARKINSON DISEASE
    Jakub Jucha, Dominik Zając, Dominika Darasz, Artur Łukawski, Lesia Slobozheniuk, Magdalena Bieniak-Pentchev, Marta Kaczorek, Krzysztof Machnik, Oliwia Dziewięcka, Wojciech Ziębka · 2026 · International Journal of Innovative Technologies in Social Science
14. Effect of Empagliflozin on Left Ventricular Myocardial Perfusion and Systolic Wall Stress Among Patients with Type 2 Diabetes
    Ashwin Padiyath, Farhad Akhavein, Otávio R. Coelho‐Filho, Subodh Verma, Adrian Quan, Hwee Teoh, C. David Mazer, Andrew Tze-Kay Yan, Kim Alexander Connelly · 2026 · CJC Open
15. Access and implementation barriers to SGLT2 inhibitor use for type 2 diabetes in Palestine: a cross-sectional health services survey of physicians
    Lisa Asad, Adham Radi, Jaser Amro · 2026 · Research Square
16. Hormonal Modulation in Chronic Coronary Syndrome: From Neurohormonal Activation to Endocrine Targets
    Alina Diduța Brie, Roxana Popescu, Cristian Mornoş, Daniel Miron Brie · 2026 · Biomedicines
17. Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data
    Omar Chebbo, François Roubille, Jean‐Luc Faillie, Nicolas Chapet, Pascale Palassin · 2026 · Therapies
18. Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists
    Omar A. Almohammed, Omar A. Alshaya, Lama A. Alduhayshi, Sara T. Alshaibani, Meshal S. Alhamed, Mohammed A. Alzeer, Othman M. Alabdullah, Mohamed F ibn Saqyan, Majed S. Al Yami, Nader Bin Sheraim et al. · 2026 · Frontiers in Endocrinology
19. CQ essential hypertension classification: The comprehensive classification to facilitate precise therapy
    Ken Chen, Chunyu Zeng · 2026 · Clinical and Experimental Hypertension
20. Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
    Bennur Esen, Damla Yıldız, Ahmet Engin Atay · 2026 · Journal of Clinical Medicine
21. Effects and Safety of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction on Dialysis
    Hao Yan, Wei Wang, Wangshu Wu et al. · 2026 · Clinical Journal of the American Society of Nephrology
22. SGLT2 inhibitors in chronic kidney disease: cardiorenal outcomes, safety, and implementation in primary care
    Shamsun Nahar, Sharar Naiarin Haque, Sananda Halder · 2026 · Exploration of Cardiology
23. IMPACTO DOS INIBIDORES DE SGLT2 NO TRATAMENTO DA SÍNDROME CARDIORRENAL
    Sofia Peruzzo Bittencourt, Fernando Tureck · 2026 · Arquivos Catarinenses de Medicina
24. Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER
    Jinqian Chen, Deyin Wang, Xiaochuan Duan, Jianbo Wang, Zhenyu Zhao, Xiaolong Xing · 2026 · Frontiers in Endocrinology
25. A familiar drug in unfamiliar territory: Will we manage to repurpose SGLT2 inhibitors in pulmonary arterial hypertension?
    Daniel A Jeffery, Mark R. Toshner, Joanna Pepke‐Żaba · 2026 · The Journal of Heart and Lung Transplantation
26. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus : final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
    智史 前川, NAKAMURA, Ichiro, Hiroshi Maegawa, Kazuyuki Tobe, Satoshi Uno · 2021 · Institutional Repositories DataBase (IRDB)
27. SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney
    Zhitong Zhou, Weijian Hang, Rui Zhao · 2026 · Bioscience Reports
28. The Portability of Surrogate Endpoints
    Henry Bair · 2026 · The Journal of Clinical Pharmacology
29. Renal outcomes associated with sodium–glucose cotransporter 2 inhibitor use in kidney transplant recipients with type 2 or posttransplant diabetes
    Guillermo Edinson Guzmán, Fabio Figueroa, Santiago Granados, Oriana Arias‐Valderrama, Jorge Giraldo, Carlos E. Durán · 2026 · Medicine
30. Sodium Glucose Co-Transporter 2 Inhibitors and Ventricular Arrhythmias in Patients with Type 2 Diabetes: A Systematic Review of Observational Studies
    Wang‐Choi Tang, Wanning Wang, Antonios Douros, Oriana Hoi Yun Yu, Robert William Platt, Kristian B. Filion · 2026 · Drug Safety
31. Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial
    Lili Sun, Guiling Liu, Baozhong Liang · 2026 · Clinics
32. Effect of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Chronic Kidney Disease Progression: A Systematic Review
    Diana D Nenova, Yanko G Yankov, Gergana M Chausheva · 2026 · Cureus
33. Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial
    Sara Kazem-Nadi, Vahid Mousavi, Zohre Labbani‐Motlagh · 2026 · Intern J Endocrinol Metab
34. SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
    Jelica Grujic-Milanovic, Jovana Rajković, Radmila Novaković, Javad Sharifi‐Rad, Daniela Cornelia Călina · 2026 · Clinical and Translational Discovery
35. Temporal Trends and Disparities in Type 2 Diabetes Mellitus and Congestive Heart Failure Mortality in the United States From 1999–2020: A CDC WONDER Analysis
    Syeda Sameen Afzal, Ittiqa Khatri, Mariam Bahzad, Zeniha Fatima, Aeman Wadood, Hasibullah Aminpoor, Maryam Sajid · 2026 · Health Science Reports
36. Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis
    Hongli Chen, Xuejie Wu, Mengyi Yuan, Feihong Ren, Tongtong Liu, Liping Yang, Xuedong An, Yongli Zhan · 2026 · Frontiers in Endocrinology
37. Pharmacological Management of Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Multi-Pillar Cardiorenal-Protective Approach
    Mosrur Ahmed · 2025 · Journal of Prevention Diagnosis and Management of Human Diseases
38. Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy
    Dan Sun, Xingjia Wang, He Wang, Zhiyi Shen, Xiangxu Meng, Yabin Zhou · 2026 · Frontiers in Endocrinology
39. Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin
    Evagelia E Habeos, Georgios Κ. Markantes, Anastasia Parthymou, Konstantinos Dimitropoulos, George I. Habeos, Marios Papasotiriou, Markos N. Marangos, Dionysios V. Chartoumpekis · 2026 · Biomedicines
40. Taiwan joint consensus on the management of osteoporosis in patients with diabetes
    Jawl‐Shan Hwang, Jung‐Fu Chen, Shih‐Te Tu, Chih‐Hsing Wu, Chih‐Yuan Wang, Der‐Sheng Han, Chun‐Chuan Lee, Chung‐Mei Ouyang, Shu‐Mei Chen, Chung‐Hwan Chen et al. · 2026 · Journal of the Formosan Medical Association
41. Increased Cardiovascular Hospitalizations Associated With Presence of Atrial Fibrillation in Acute Coronary Syndrome Patients: A Double Trouble Situation
    Murat Gençaslan, Ceyhun Yücel, Mustafa Lütfullah Ardıç · 2026 · Catheterization and Cardiovascular Interventions
42. Long-Term Mortality with Contemporary Multivessel PCI Versus CABG in Patients with Diabetes and Multivessel Disease: A Population-Based Retrospective Cohort Study
    Xiang Xiao, Anamaria Savu, Kevin R. Bainey · 2026 · medRxiv
43. Смена парадигмы лечения сахарного диабета 2-го типа – от метаболической коррекции к органопротекции
    Т.В. Мохорт · 2026 · Кардиология в Беларуси
44. A prediction nomogram for sodium-glucose co-transporter 2 inhibitors-induced diabetes ketoacidosis in non-surgical patients: a retrospective multicenter cohort study
    Danxia Chen, Zongshuai Gao, Jian Wang, Yunxia Zhu, Jianwei Wan, Weijun Tang, Xiaojing Jiao, Yabin Ma, Feng Zhu, Xiucong Fan · 2026 · Frontiers in Endocrinology
45. Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes
    Panupong Hansrivijit, Elisabetta Patorno, Helen Tesfaye, Deborah J. Wexler, Miin Roh, Julie M. Paik · 2026 · Kidney Medicine
46. Effect of sodium-glucose cotransporter-2 inhibitors on electrocardiographic markers of ventricular repolarization: A systematic review and meta-analysis
    Muhammad Ghifari Karsa, Viyola Rahma, Muhammad Iqhramullah, Muhammad Habiburrahman · 2026 · American Heart Journal Plus Cardiology Research and Practice
47. Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
    Philip Branigan, Vo Nhu Y Duong, Stephanie Branigan · 2026 · Cureus
48. Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection
    Madison L. Wise, Abdel A. Alli · 2026 · Pathophysiology
49. ИЗУЧЕНИЕ ГИПОГЛИКЕМИЧЕСКОГО И КАРДИОПРОТЕКТИВНОГО ЭФФЕКТА ЭМПАГЛИФЛОЗИНА В ТЕРАПИИ БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА
    Дилором Анваровна Урунбаева, Д. К. Нажмутдинова, N G Sadikova · 2023 · Research Focus International Scientific Journal
50. The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice
    Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu · 2026 · Diabetes Obesity and Metabolism
51. Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes
    Quan Đức Minh Nguyen, Khoa Dang Dang Tran, Son Kim Tran · 2026 · Medicine
52. Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
    Muhammad Shariq Usman, Subodh Verma, Ambarish Pandey · 2026 · Handbook of experimental pharmacology
53. Inercia terapéutica en el tratamiento de la diabetes mellitus tipo 2: una brecha que urge cerrar
    Antoni Sicras Mainar · 2026 · Endocrinología Diabetes y Nutrición
54. SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury
    Dianet Sanchez Vega, Ellen Oskoui, Leah J. Siskind · 2026 · Handbook of experimental pharmacology
55. Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
    Ele Ferrannini · 2026 · Handbook of experimental pharmacology
56. Effect of dapagliflozin on electrocardiographic arrhythmic markers in patients with type 2 diabetes mellitus
    Gülüzar Traş, Fuat Polat, Melike Saday Bozkurt · 2026 · British Journal of Clinical Pharmacology
57. Knowledge, Prescribing Practices, and Perceived Barriers Regarding Novel Glucose-Lowering Medications Among Community Physicians: A Cross-Sectional Survey Across 36 Primary Healthcare Institutions in Pudong, Shanghai
    Yanru Liu, Xiaolin Liu, Peipei Gao · 2026 · Research Square
58. Sodium-Glucose Cotransporter 2 Inhibitor Use and Functional Outcomes After Endovascular Thrombectomy in Diabetic Stroke
    Wookjin Yang, Ji Sung Lee, Bum Joon Kim, Jun Young Chang, Dong‐Wha Kang, Sun U. Kwon, Eung‐Joon Lee, Jeong‐Min Kim, Keun‐Hwa Jung, Seung‐Hoon Lee et al. · 2026 · Stroke
59. Geriatrische Aspekte bei Diabetes mellitus (Update 2026)
    Joakim Huber, Michael Smeikal, Christoph H. Saely, Harald Stingl, Monika Lechleitner, Peter Fasching · 2026 · Wiener klinische Wochenschrift
60. Mitohormesis linking metabolic dysfunction and neurodegeneration: implications for dementia and therapeutic strategies
    Toshiki Otoda, Hideto Nakajima, Tadateru Takayama · 2026 · Frontiers in Molecular Neuroscience
61. Empagliflozin
    Emily Eddy, Brittany Long, Taryn Sandei, Mason Meyer · 2026 · Elsevier eBooks
62. SGLT2i use and fracture risk compared with DPP4i in patients with T2DM
    Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang · 2026 · Journal of Diabetes Investigation
63. Clinical Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients Undergoing Mitral Transcatheter Edge‐to‐Edge Repair
    Farah Yasmin, Mohammad Hamza, Muhammad Ahmed Ali Fahim, Barka Sajid, Mahnoor Humayun, Rohan Kumar Ochani, Muhammad Sohaib Asghar, M. Chadi Alraies · 2026 · Catheterization and Cardiovascular Interventions
64. Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives
    Himanshu, Suryakant Verma, Sonam Yadav, Asmita Singh, Jaishiv Chauhan, Sameeksha, Kshitiz Sahu, Anup K Mamgain · 2026 · Discover Endocrinology and Metabolism
65. RESISTENCIA A LA INSULINA EN LA DIABETES MELLITUS TIPO 2 Y SU PAPEL EN LA PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA Y LAS COMPLICACIONES CARDIOVASCULARES: UNA REVISIÓN NARRATIVA CRÍTICA CON BÚSQUEDA ESTRUCTURADA
    Telmo Eduardo Salas Joya, Leonardo Lanzee Mendoza Jiménez, Evelyn Ileana Reyes Yagual · 2026 · VitalyScience Revista Científica Multidisciplinaria
66. Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives
    Emmanuel Andrès, N. Lorenzo-Villalba, N. Dali-Youcef · 2026 · Journal of Clinical Medicine
67. Prise en charge thérapeutique du diabète de type 2
    Vincent Rigalleau, B. Cherifi, L. Blanco, Alice Larroumet, Ninon Foussard, Kamel Mohammedi · 2026 · EMC - Traité de médecine AKOS
68. Multi-omics analysis reveals TCA cycle and mitochondrial metabolic remodeling associated with astragaloside IV-mediated cardioprotection
    Jinxuan Chai, Yan Wang, Xiaoqing Zhang et al. · 2026 · Journal of Agriculture and Food Research
69. Risk Assessability and Recorded Organ-Protective Therapy Gaps in Type 2 Diabetes: A Five-Center Cross-Sectional Study
    wenxuan li, Jinghan Zheng, Wenshan Lv, lili xu, Ke Si, Yuzhao Liu, Shuhui Hu, Shengli Wu, Yuancheng Dai, Qijuan Dong et al. · 2026 · Research Square
70. Effect of glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors alone and in combination on AF recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation
    Adham Ramadan, Mohamed Doma, Mohammad Hosein Yazdanpanah, Farhan Naeem, Leon M. Ptaszek, Jeremy Neil Ruskin · 2026 · Heart Rhythm
71. Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies
    Yajing Bai, Yinghong Bai, Shiwei Liu · 2026 · iScience
72. The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care
    Ashutosh Mishra, Pallavi mishra, Sarita Bajaj, Pramila Kalra, Vinaytosh Mishra, Smitha Bhat, Bijay Patni, Vinod K. Abichandani, Faraz Farishta, Vikas Aggarwal et al. · 2026 · The Lancet Regional Health - Southeast Asia
73. Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
    Natsuko Shinagawa, Hiroshi Okada, Junya Hironaka et al. · 2026 · Journal of Diabetes Investigation
74. Diabetes Medication Regimen Complexity and Glycemic Outcomes among Medically Underserved Latino Adults: Implications for Pharmacoequity
    Cheryl Wisseh, Jaylen Lee, Margarita Loeza · 2026 · Journal of Immigrant and Minority Health
75. Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study
    Luise Bellach, Sarah Hofer-Zeni, Dorota Sluková, Dorothea Kalender, Clemens Zimmermann, Naima Michler, Liliana Gard, Sabina M. Baumgartner-Parzer, Rodrig Marculescu, Greisa Vila et al. · 2026 · Cardiovascular Diabetology
76. Outcomes of SGLT2 inhibitors after transcatheter mitral valve repair in patients with type 2 diabetes mellitus
    Mahmoud Abdelnabi, Hoang Nhat Pham, Ramzi Ibrahim, Mohamed Allam, Girish Pathangey, Min Choon Tan, Kwan Lee, Floyd David Fortuin, Said Alsidawi, Chadi Ayoub et al. · 2026 · Journal of Cardiovascular Medicine
77. Mitochondrial Dynamics in Diabetes Mellitus and Its Complications: Mechanisms, Pathological Roles, and Therapeutic Implications
    Guohua Wang, Yige Zhao, Gaiting Liu, Yuhang Du, Shuchang Liu, Yang Yang, Sitong Bu, Baosheng Zhao · 2026 · International Journal of Molecular Sciences
78. Emerging Evidence on Molecular Dysregulation Driving Cardiomyopathies and Heart Failure
    Alberto Guarnaccia, Davide Miglietta, Maria Perotto, Matteo Dal Ferro, Serena Zacchigna, Marco Merlo, Gianfranco Sinagra · 2026 · Springer eBooks
79. Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors
    Anna Solini, Domenico Tricò · 2026 · Handbook of experimental pharmacology
80. Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
    Kaitlin J. Mayne, Matthew M.Y. Lee, Naveed A. Sattar, William Guy Herrington · 2026 · European Journal of Internal Medicine
81. Drug Development and Promising Therapeutic Targets for Coronary Artery Disease: Current Landscape and Future Prospects: CVIA State-of-the-Art Review
    Shan Hu, Zhen Guo, Chenze Li, Xiang Nie, Jinjie Wang, Jianmei He, Cheng Zhuang, Limin Zhang, Depeng Li, Yutong Lin et al. · 2026 · Cardiovascular Innovations and Applications
82. Effects of SGLT2 Inhibitors in Rodent Models of Diabetic Nephropathy
    Aqsa Ashfaq, Andrea Pautz, Ebru Arioglu‐Inan, Martin Christian Michel · 2026 · Handbook of experimental pharmacology
83. A study on the effect of the antidiabetic, empagliflozin, and the adjuvant agent, zinc on the blood pressure and the diabetes induced biochemical changes in diabetic albino
    Mohammed Azhar, Rahma Hassan H.A., Elsisi Ahmed A.R. · 2026 · Al-Azhar Assiut Medical Journal
84. The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer’s Disease
    Sodiq Fakorede, Olubodun Michael Lateef, Augustine Lishilinimye Udefa, Abayomi Oyeyemi Ajagbe͓, Sharmistha Roy, Priscilla Onaopemipo Akosile, Taiwo Ayomide Awobona, Godson Emeka Anyanwu · 2026 · Molecular Neurobiology
85. Subclinical Diabetic Cardiomyopathy: Detectable but Not Yet Actionable
    Avnish Tripathi · 2026 · Journal of the American Heart Association
86. Diabetic Heart Failure: Epidemiology and Prognosis
    D. Bamba-Kamagaté, Kee Mankoh Yves-Cédric, Kanga Koffi Guy Stéphane, Koffi Florent, Daniogo Mbe Matokoma, Esther Ehouman, Anzouan-Kacou Jean-Baptiste · 2026 · Journal of Cardiac Critical Care TSS
87. Semaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementation
    Fayez Salahedin Alkhateeb · 2026 · SN Comprehensive Clinical Medicine
88. Pharmacoeconomic Analysis of the Use of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes in Bosnia and Herzegovina
    Adna Jabandžić, Adna Ašić, Lejla Gurbeta Pokvić · 2026 · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany
89. Risk factors for recurrent urinary tract infection after SGLT2 inhibitor reinitiation in type 2 diabetes
    Yu-Chu Hsueh, Chia-Hung Lin, Pi-Hua Liu, Yi-Hsuan Lin · 2026 · Endocrine
90. Association between renal and cerebral vascular parameters in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: a prospective observational study
    Elham M. Yousief, Heba Mahmoud Ibrahim · 2026 · International Journal of Diabetes in Developing Countries
91. Effects of Sodium‐Glucose Cotransporter‐2 Inhibitors on Inflammatory Biomarkers: A Systematic Review and Meta‐Analysis
    Mehmet Kanbay, Ermeena Shah, Rama Al-Shiab, Aladin Rustamov, Sedat Ay, Mustafa Güldan, Katherine R. Tuttle, Francesca Mallamaci, Carmine Zoccali · 2026 · Diabetes Obesity and Metabolism
92. Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis
    Rosa Yang, Kevin Cho, Max C. Petersen, Kai E. Jones, Gary J. Patti, Janet B. McGill, Samantha E. Adamson · 2026 · Diabetes Obesity and Metabolism
93. Appropriate glycated haemoglobin testing frequency to monitor patients with type 2 diabetes
    Wade Thompson, Thomas L. Perry, Guillaume Grenet · 2026 · African Journal of Primary Health Care & Family Medicine
94. Berberine attenuates diabetic kidney injury via FOXO1/SP1-associated regulation of renal SGLT-2 expression
    Jingjing Pan, Xinhe Wang, Xinyuan Han, Hui Cheng, Fengyi Zhang, Yaxin Chen, Changnian Li, Xin Wang, Ziyang Cheng, Yu Zhang et al. · 2026 · Chinese Medicine
95. Heart Failure: Lipid Metabolism Disorders Driving Cellular Senescence Through a Vicious Cycle, and Possible Intervention Strategies
    Wei He, Pan Liu, Jingjing Kong, Qing Wang, Yangqi Zhao, Ran Xia · 2026 · Frontiers in Bioscience-Landmark
96. Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors: A Real-World Active Comparator Study
    Valentin Milanov · 2026 · Endocrine Practice
97. Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Decompensated Heart Failure: Efficacy, Safety, and Implementation in Stabilized Patients
    Alfredo Mauriello, Adriana Correra, Anna Chiara Maratea, Valeria Cetoretta, Francesco Giallauria, Giovanni Esposito, Alfonso Desiderio, Francesco Sabatella, Renato Gioia, Gemma Marrazzo et al. · 2026 · Reviews in Cardiovascular Medicine
98. SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis
    Marconi Abreu, Paula C N Santos, Naim M. Maalouf, Khashayar Sakhaee, Gaspar R. Chiappa · 2026 · Endocrine Practice
99. The Role of Glycolysis in Diabetic Kidney Disease
    Yifan Wang, Xin Jiang, Liwen Cui, YONGKE YOU, Wenjuan Zhu, Chongfei Jiang, Zhouning Liao, Jianbo Guo, Hao Lu, Baoyi Shao et al. · 2026 · International Journal of Molecular Sciences
100. Metformin, SGLT2 Inhibitors, and Intermittent Fasting: Convergent Pathways to Healthspan Extension, Cardiovascular Longevity, and Cancer Prevention—A Narrative Review
     Dragoș Constantin Cozma, Cristina Tudoran, Cristina Văcărescu · 2026 · Current Issues in Molecular Biology